Shattuck Labs reports Q4 2022 net loss of $25.4M, discontinues SL-279252 program

Shattuck Labs, Inc.

2022-FY EPS reported -$2.41 revenue$652,000

Net loss Q4 2022 $25.4M ($0.60/share) vs net income $7.8M in Q4 2021; full-year net loss $101.9M.
Cash and investments $161.3M at Dec 31, 2022, down from $268.8M; cash runway into H2 2024.
Discontinued SL-279252 program after Phase 1 failed to meet 20% response rate threshold.
Initiated Phase 1B trial of SL-172154 + mirvetuximab soravtansine in ovarian cancer; dosed first patients with azacitidine in AML/HR-MDS.
Appointed Dr. George Fromm as CSO of ARC platform and Dr. Suresh de Silva as CSO of GADLEN platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Shattuck Labs, Inc. reported financial results for the three months and year ended December 31, 2022.

Period: the three months and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the three months and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-23-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.